Ave Maria Biotech, Inc. (AMB) was founded in direct response to the global health vulnerabilities exposed by the COVID-19 outbreak. The Company’s flagship device, the BD-500, offers real-time detection of airborne viruses and other pathogens, empowering businesses, healthcare facilities, the military, and public spaces to take immediate action based on accurate data. Today AMB works in a Cooperative Research and Development Agreement with US Army DEVCOM.